

Implantate bei Antiresorptiva-Patienten

Dr. Tim F. Wolff, Prof. Dr. Dr. Knut A. Grötz

ZMK 9 (35, S. 569-575)

1. Walter C et al.: Zahnimplantate bei medikamentöser Behandlung mit Knochenantiresorptiva (inkl. Bisphosphonate) – S3-Leitlinie (Langversion), Stand: Juli 2016. Available from: <http://www.awmf.org/leitlinien/detail/ll/083-026.html>. 2016.
2. Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. *J Oral Maxillofac Surg* 61 (9), 1115–1117 (2003).
3. Grötz KA, Schiegnitz E, Wolff TF: Handbuch ZMK 2015: ZMK-Update 2015 Risikopatienten in der ZMK (inkl. Impl. bei Risikopatienten), Wiesbaden Grötz K. A.; Frankfurt Lauer H.-C.; Freiburg Hellwig E., ISBN 9783863021450. 2015.
4. Grötz KA, Piesold J-U, Al-Nawas B: S3-Leitlinie: Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. AWMF 007-091 (2012).
5. Smith MR et al.: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. *Lancet* 379 (9810), 39–46 (2012).
6. Qi WX et al.: Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. *Int J Clin Oncol* 19 (2), 403–410 (2014).
7. Guarneri V et al.: Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. *Breast Cancer Res Treat* 122 (1), 181–188 (2010).
8. Christodoulou C et al.: Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. *Oncology* 76 (3), 209–211 (2009).
9. zm-online. Rote-Hand-Brief für Zaltrap. Available from: http://www.zm-online.de/hefte/Rote-Hand-Brief-fuer-Zaltrap_344687.html (2016).
10. Pilanci KN et al.: Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment? *Medicine (Baltimore)* 94 (18), e671 (2015).
11. Ponzetti A et al.: Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. *Tumori* 0(0): 0 (2015).
12. Walter C et al.: Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. *Head Face Med* 6 (1), 11 (2010).
13. Walter C et al.: Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. *Eur Urol* 54 (5), 1066–1072 (2008).
14. Rahimi-Nedjat RK et al.: Diabetes mellitus and its association to the occurrence of medication-related osteonecrosis of the jaw. *Dentistry Journal* 4 (2), 1–7 (2016).
15. Grötz KA, Al-Nawas B. Laufzettel Biophosphonate Risiko-Evaluation bei antiresorptiver Therapie vor Implantation. Available from: <https://www.dginet.de/web/dgi/laufzettel-bisphosphonate> (2013).
16. Walter C et al.: Dental implants in patients treated with antiresorptive medication - a systematic literature review. *Int J Implant Dent* 2 (1), 9 (2016).

Kommentar [AK1]: ??

17. Grötz KA, Al-Nawas B: Persisting alveolar sockets-a radiologic symptom of BP-ONJ? J Oral Maxillofac Surg 64 (10), 1571–1572 (2006).
18. Kumar MN, Honne T: Survival of dental implants in bisphosphonate users versus non-users: a systematic review. Eur J Prosthodont Restor Dent 20 (4), 159–162 (2012).
19. Grötz KA, Schiegnitz E, Wolff TF: Handbuch MKG 2016: MKG-Update 2016 ONKO II: SUPPORTIVE TU-BETREUUNG. Wiesbaden: Groetz, Knut A., Wiesbaden; Haßfeld, Stefan, Dortmund; Schmidt-Westhausen, Andrea M, Berlin; ISBN 978-3-86302-290-7. (2016).
20. Kasai T, Pogrel MA, Hossaini M: The prognosis for dental implants placed in patients taking oral bisphosphonates. J Calif Dent Assoc 37 (1), 39–42 (2009).
21. Grötz KA, Al-Nawas B, Terheyden H: Implantate und Bisphosphonat-Therapie. Implantologie 21 (1), 53–59 (2013).
22. Chadha GK et al.: Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: a systematic review. J Oral Implantol 39 (4), 510–520 (2013).